- Home
- FCBC vs MNKD Comparison
FCBC vs MNKD Comparison
Compare FCBC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCBC | MNKD |
|---|---|---|
| Founded | 1874 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 790.7M | 877.0M |
| IPO Year | 1996 | 2004 |
Fundamental Metrics
Financial Performance| Metric | FCBC | MNKD |
|---|---|---|
| Price | $42.37 | $3.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.69 |
| AVG Volume (30 Days) | 56.3K | ★ 6.0M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | $12.28 | $35.81 |
| Revenue Next Year | $2.55 | $11.89 |
| P/E Ratio | $67.17 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $31.21 | $2.23 |
| 52 Week High | $44.36 | $6.51 |
Technical Indicators
Market Signals| Indicator | FCBC | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 59.70 |
| Support Level | $42.14 | $2.45 |
| Resistance Level | $44.20 | $6.08 |
| Average True Range (ATR) | 1.09 | 0.26 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 49.56 | 34.25 |
Price Performance
Historical ComparisonAbout FCBC First Community Bankshares Inc. (VA)
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.